Analysis

Moving on from where the Cancer Drugs Fund failed

When the Cancer Drugs Fund was launched in 2010, it was hailed as the solution to getting patients access to innovative drugs. It has since become a fixture in the health service in England.

When the Cancer Drugs Fund was launched in 2010, it was hailed as the solution to getting patients access to innovative drugs. It has since become a fixture in the health service in England.

But the hopes have now given way to a widespread consensus that it is unsustainable in its current form. Last month NHS England announced that 16 medicines used in 23 separate cancer treatments would be taken off the approved list from November.

It means the number of treatments paid for by the fund has been halved to 41 since the beginning of the year as NHS England has tried to keep the lid on spiralling spending.

Spending

The budget has already been increased by £60 million to £340 million this year to help keep pace with demand, but without the new round of de-listing, NHS England warned spending would have topped £400

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs